Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
A legfontosabb adatok
- Hol
- Miami (Egyesült Államok)A helyszín megnézése
- Fázis
- 2. fázis
Helyszínek itt: Egyesült Államok
- University of Miami Hospital and ClinicsMiami, Egyesült ÁllamokContact: Kelly Corbitt, D.O.Résztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- University of Miami
- Azonosító
- NCT07486869
- A regiszteradat frissítve
- 2026. augusztus 25.
- Eredeti leírás
This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.A teljes eredeti leírásKevesebb
Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease
This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.
Bevonási feltételek: Progressive interstitial lung disease as determined by at least 2/4 of the following:; worsening respiratory symptoms; worsening or new oxygen requirement; worsening disease on CT chest; worsening Forced Vital Capacity (FVC1) or Diffusing Capacity for Carbon Monoxide (DLCO) on pulmonary function tests; MDA5 antibodies present; Elevated ferritin above the upper limit of normal (ULN); Participant at least 18 years old.
Kizáró feltételek: Active, untreated bacterial, mycobacterial or fungal infection; Active herpes zoster infection; Currently requiring extracorporeal membrane oxygenation (ECMO); Participant refusal to participate in the study; Pregnant women; Prisoners.